First-in-human, Single Ascending Dose Study of CEL383 in Healthy Adult Subjects

Study Identifier
383-001
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Study Details

Medical Condition
  • Healthy Volunteer
  • Study Drug
  • CEL383
  • Placebo
  • Phase
    Phase 1
    Sex
    Female & Male
    Age
    19 - 64 Years

    Protocol Summary

    This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of CEL383 in healthy volunteers.

    Study Locations

    Location
    Status
    Location
    Celerion
    Lincoln, Nebraska, United States, 68502
    Status
    Not applicable